Evolving treatment strategies for management of cardiorenal syndrome

Current Treatment Options in Cardiovascular Medicine

Volumn 13, Issue 6, 2011, Pages 556-569

  Dandamudi, Sanjay ^a   Chen, Horng H ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; BUMETANIDE; CONIVAPTAN; DOPAMINE; FENOLDOPAM; FUROSEMIDE; LOOP DIURETIC AGENT; NESIRITIDE; PLACEBO; ROLOFYLLINE; SILDENAFIL; SODIUM CHLORIDE; TOLVAPTAN; TORASEMIDE;

ACUTE HEART FAILURE; ARTICLE; BACTERIAL INFECTION; CLINICAL EFFECTIVENESS; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; ELECTROLYTE DISTURBANCE; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE ISCHEMIA; HORMONAL REGULATION; HUMAN; HYPERURICEMIA; HYPOTENSION; HYPOVOLEMIA; INJECTION SITE REACTION; INTERMETHOD COMPARISON; KIDNEY DENERVATION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIMB ISCHEMIA; LOADING DRUG DOSE; LOW DRUG DOSE; NONHUMAN; OTOTOXICITY; RECOMMENDED DRUG DOSE; RENAL REPLACEMENT THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 81155139628     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-011-0148-3     Document Type: Article

References (45)

1. VL Roger, et al. 2011 Heart disease and stroke statistics-2011 update: a report from the American Heart Association Circulation 123 e18 e209 21160056 10.1161/CIR.0b013e3182009701
2. DE Forman, et al. 2004 Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure J Am Coll Cardiol 43 61 67 14715185 10.1016/j.jacc.2003.07.031 (Pubitemid 38045917)
3. HL Hillege, et al. 2000 Renal function, neurohormonal activation, and survival in patients with chronic heart failure Circulation 102 203 210 10889132 1:STN:280:DC%2BD3czkvFeqtQ%3D%3D (Pubitemid 30451778)
4. C Ronco, et al. 2008 Cardiorenal syndrome J Am Coll Cardiol 52 1527 1539 19007588 10.1016/j.jacc.2008.07.051
5. RW Schrier WT Abraham 1999 Hormones and hemodynamics in heart failure N Engl J Med 341 577 585 10451464 10.1056/NEJM199908193410806 1:CAS:528: DyaK1MXlvVOnsbY%3D (Pubitemid 29384167)
6. K Damman, et al. 2009 Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease J Am Coll Cardiol 53 582 588 19215832 10.1016/j.jacc.2008.08.080
7. W Mullens, et al. 2009 Importance of venous congestion for worsening of renal function in advanced decompensated heart failure J Am Coll Cardiol 53 589 596 19215833 10.1016/j.jacc.2008.05.068
8. SS Gottlieb, et al. 2002 BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy Circulation 105 1348 1353 11901047 10.1161/hc1102.105264 1:CAS:528:DC%2BD38XjtFalsL4%3D (Pubitemid 34260427)
9. MW Vogel HH Chen 2011 Novel natriuretic peptides: new compounds and new approaches Curr Heart Fail Rep 8 22 27 21128026 10.1007/s11897-010-0038-0 1:CAS:528:DC%2BC3MXhtVWlur0%3D
10. Chen HH, Burnett Jr JC. The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc Assoc Am Physicians. 1999;111:406-16. (Pubitemid 29446883)
11. WF Peacock, et al. 2009 Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry Cardiology 113 12 19 18931492 10.1159/000164149
12. W Mullens, et al. 2008 Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J Am Coll Cardiol 51 300 306 18206740 10.1016/j.jacc.2007.09.043
13. Salvador DR, et al. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev. 2005;CD003178.
14. GM Felker, et al. 2011 Diuretic strategies in patients with acute decompensated heart failure N Engl J Med 364 797 805 21366472 10.1056/NEJMoa1005419 1:CAS:528:DC%2BC3MXivV2ktrg%3D
15. R Lemmens-Gruber M Kamyar 2006 Vasopressin antagonists Cell Mol Life Sci 63 1766 1779 16794787 10.1007/s00018-006-6054-2 1:CAS:528:DC%2BD28XoslWrsbc%3D (Pubitemid 44223085)
16. JE Udelson, et al. 2001 Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure Circulation 104 2417 2423 11705818 10.1161/hc4501.099313 1:CAS:528:DC%2BD3MXpt1KhsL4%3D (Pubitemid 33108374)
17. M Gheorghiade, et al. 2004 Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial JAMA 291 1963 1971 15113814 10.1001/jama.291.16.1963 1:CAS:528:DC%2BD2cXjs1ajsb8%3D (Pubitemid 38544277)
18. MA Konstam, et al. 2007 Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial JAMA 297 1319 1331 17384437 10.1001/jama.297.12.1319 1:CAS:528:DC%2BD2sXjs1ejtrg%3D (Pubitemid 46513233)
19. SS Gottlieb 2008 Adenosine A1 antagonists and the cardiorenal syndrome Curr Heart Fail Rep 5 105 109 18765081 10.1007/s11897-008-0017-x 1:CAS:528:DC%2BD1cXhtV2htrbP
20. BM Massie, et al. 2010 Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure N Engl J Med 363 1419 1428 20925544 10.1056/NEJMoa0912613 This trial assessed the use of rolofylline in the treatment of acute heart failure but failed to demonstrate a beneficial effect in improving symptoms or preventing readmissions and overall mortality when compared to placebo. Rolofylline also failed to demonstrate improvement in renal function.
21. JW Cheng 2002 Nesiritide: review of clinical pharmacology and role in heart failure management Heart Dis 4 199 203 12028606 10.1097/00132580- 200205000-00011 1:CAS:528:DC%2BD38Xpsleqsrc%3D (Pubitemid 34670488)
22. JD Sackner-Bernstein HA Skopicki KD Aaronson 2005 Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure Circulation 111 1487 1491 15781736 10.1161/01.CIR.0000159340.93220.E4 1:CAS:528:DC%2BD2MXisVGrtLg%3D (Pubitemid 40470642)
23. RM Witteles, et al. 2007 Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial J Am Coll Cardiol 50 1835 1840 17980248 10.1016/j.jacc.2007.03.071 1:CAS:528:DC%2BD2sXht1GlurzM (Pubitemid 350007964)
24. HG Riter, et al. 2006 Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction J Am Coll Cardiol 47 2334 2335 16750705 10.1016/j.jacc.2006.03.013 1:CAS:528:DC%2BD28Xmt1Kit7Y%3D (Pubitemid 43795074)
25. AF Hernandez, et al. 2009 Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF) Am Heart J 157 271 277 19185633 10.1016/j.ahj.2008.07.031 1:CAS:528:DC%2BD1MXhtlSktrY%3D
26. JD Horowitz, et al. 2011 Clinical Trials Update AHA Congress 2010 Cardiovasc Drugs Ther 25 69 76 21340529 10.1007/s10557-011-6285-9
27. LI Goldberg 1989 Pharmacological bases for the use of dopamine and related drugs in the treatment of congestive heart failure J Cardiovasc Pharmacol 14 S21 S28 2483439 10.1097/00005344-198907000-00001 1:CAS:528:DyaK3cXhtlams74%3D
28. JO Friedrich, et al. 2005 Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death Ann Intern Med 142 510 524 15809463 1:CAS:528:DC%2BD2MXjslCqsL4%3D
29. Heart Failure Network: ROSE Trial. Available at https://www.hfnetwork. org/hf-trials/rose-trial. Accessed June 2011.
30. SM Udani PT Murray 2009 The use of renal replacement therapy in acute decompensated heart failure Semin Dial 22 173 179 19426424 10.1111/j.1525-139X. 2008.00542.x
31. MR Costanzo, et al. 2010 Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD J Card Fail 16 277 284 20350693 10.1016/j.cardfail.2009.12.009 This trial confirmed that compared to a standard diuretic regimen, ultrafiltration was associated with a greater change in weight loss and fluid removal at 48 hours with no difference in subjective dyspnea. The rates of rehospitalization and total days of hospitalization were also significantly lower at 3 months but with no associated difference in mortality.
32. Heart Failure Network: CARRESS-HF Trial. Available at https://www.hfnetwork.org/hf-trials/carress-trial. Accessed June 2011.
33. SK Swan 1994 Diuretic strategies in patients with renal failure Drugs 48 380 385 7527759 10.2165/00003495-199448030-00005 1:STN:280: DyaK2M%2FoslGlsQ%3D%3D (Pubitemid 24264275)
34. S Paterna, et al. 2005 Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double blind study J Am Coll Cardiol 45 1997 2003 15963399 10.1016/j.jacc.2005.01.059 1:CAS:528:DC%2BD2MXlt1WhsL0%3D (Pubitemid 40814121)
35. G Licata, et al. 2003 Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects Am Heart J 145 459 466 12660669 10.1067/mhj.2003.166 1:CAS:528:DC%2BD3sXisFSgt7k%3D (Pubitemid 36390492)
36. HH Chen, et al. 2009 Local renal delivery of a natriuretic peptide: a renal-enhancing strategy for B-type natriuretic peptide in overt experimental heart failure J Am Coll Cardiol 53 1302 1308 19358945 10.1016/j.jacc.2009.01.030 1:CAS:528:DC%2BD1MXktlyqtLk%3D
37. PS Teirstein, et al. 2006 Differential effects between intravenous and targeted renal delivery of fenoldopam on renal and blood pressure in patients undergoing cardiac catheterization Am J Cardiol 97 1076 1081 16563920 10.1016/j.amjcard.2005.10.053 1:CAS:528:DC%2BD28XivVaqtL0%3D
38. CY Lee H Lieu JC Burnett Jr 2009 Designer natriuretic peptides J Investig Med 57 18 21 19158603 This articles describes the engineering behind chimeric natriuretic peptides and their potential therapeutic use in heart failure.
39. O Lisy, et al. 2008 Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP J Am Coll Cardiol 52 60 68 18582636 10.1016/j.jacc.2008.02.077 1:CAS:528:DC%2BD1cXnvVGlt7k%3D (Pubitemid 351852935)
40. PJ Hunt, et al. 1994 Bioactivity and metabolism of C-type natriuretic peptide in normal man J Clin Endocrinol Metab 78 1428 1435 8200946 10.1210/jc.78.6.1428 1:CAS:528:DyaK2cXksFSks7Y%3D (Pubitemid 24181016)
41. CY Lee, et al. 2009 Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects J Clin Pharmacol 49 668 673 19395584 10.1177/0091270009336233 1:CAS:528: DC%2BD1MXmvVOruro%3D This was the first in-human clinical trial of CD-NP, which confirmed its favorable natriuretic and renal-preserving effects in the absence of excessive hypotension in healthy subjects.
42. SD Katz 2003 Potential role of type 5 phosphodiesterase inhibition in the treatment of congestive heart failure Congest Heart Fail 9 9 15 12556672 10.1111/j.1527-5299.2002.00288.x 1:CAS:528:DC%2BD3sXhs1Wktbc%3D (Pubitemid 36358347)
43. T Supaporn, et al. 1996 Blunted cGMP response to agonists and enhanced glomerular cyclic 3′,5′-nucleotide phosphodiesterase activities in experimental congestive heart failure Kidney Int 50 1718 1725 8914042 10.1038/ki.1996.491 1:CAS:528:DyaK28Xms1yks74%3D (Pubitemid 26364281)
44. HH Chen, et al. 2006 Maximizing the renal cyclic 3′-5′- guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure J Am Soc Nephrol 17 2742 2747 16928803 10.1681/ASN.2006020161 1:CAS:528:DC%2BD28XhtFWksLfE (Pubitemid 44484664)
45. H Krum, et al. 2009 Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study Lancet 373 1275 1281 19332353 10.1016/S0140-6736(09)60566-3